INS and myotonic dystrophy type 2: In participants with DM2, quality of life was different between the types of insulin therapy (basal insulin: − 0.5 ± 0.5, premixed insulin: − 1.8 ± 0.4, short acting insulin: − 2.1 ± 1.7, short acting/basal insulin: − 1.5 ± 1.2, insulin pump: − 2.4).